Generic Semaglutide Availability to Expand

The patent for semaglutide, the active ingredient in Ozempic and Wegovy, is beginning to expire in key international markets. While U.S. patents are protected until at least December 2031 due to extensions, patents in countries like India, Brazil, and Canada are set to lapse around March 2026, opening the door for generic competition. A wave of pharmaceutical companies is preparing to enter the market. Indian drugmakers like Dr. Reddy's Laboratories and Zydus Lifesciences are planning launches as soon as the patent expires in India. Globally, companies including Sandoz, Biocon, and at least 15 firms in China are also developing their own versions. The cost differential is expected to be significant. Brand-name semaglutide injections like Ozempic and Wegovy can cost between $900 and $1,300 per month in the U.S. without insurance. Generic versions are anticipated to trigger price drops of at least 50-60%. The market for generic semaglutide represents a massive opportunity, with analysts estimating a potential revenue pool exceeding Rs. 50,000 crores (approximately $6 billion USD) for generic drugmakers in India and other emerging markets in the first 12-15 months. To gain approval, generic manufacturers use an Abbreviated New Drug Application (ANDA). This process doesn't require new clinical trials but mandates proof that the generic has the same active ingredient, strength, and performance (bioequivalence) as the brand-name drug. In the U.S., currently available lower-cost options are typically "compounded semaglutide," not true generics. These are custom-made by specialized pharmacies, a practice permitted by the FDA during official drug shortages, but they do not undergo the same FDA approval process as authorized generics. Original manufacturer Novo Nordisk is not standing still. The company is reportedly considering launching its own lower-priced, authorized versions of semaglutide under new brand names to compete directly with the forthcoming generics.